The purpose is to find out how much medication is in breastmilk after intake.

This will help us determine the daily dose a child could potentially be exposed to during breastfeeding, if the nursing mother must take this medicinal product. 


This study is seeking healthy breastfeeding female participants.

Download the informed consent form


Healthy lactating women who agree to temporally interrupt breastfeeding their child for 4.5 days


18 - 55



Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

View more eligibility criteria


The study is planned to last for approximately 9 weeks.

Several examinations or procedures will be required in connection with the study:

  1. A screening examination, during which you will sign a COVID ICD and the study ICD;
  2. COVID-19 assessments during residence in the PCRU
  3. One treatment period organized of 5 days and 4 nights in the PCRU (from Day -1 to Day 4).
  4. The follow-up phone call will take place 28 to 35 days after the last administration of the study medicine.

You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.

Download the informed consent form

Long-term follow-up

a follow-up call at the end of the study

How long is the study?

Approximately 9 weeks


€ 1.670 upon completion of the study, €120 Covid and transportation fees




0800.99.256 (フリーダイヤル:ベルギーから)、00800.フリーダイヤル:イギリス、フランス、ドイツ、オランダから)、+有料ダイヤル:上記以外の国から)に電話し、担当者に詳細をお問い合わせください。または、以下の登録フォームに入力してご送信ください。